BackENDRA Life Sciences- Warrants (12/05/2022) Overview

ENDRA Life Sciences- Warrants (12/05/2022) Long Term Debt

Latest long-term debt for NDRAW: $330K.

Get informed when a big investor buys or sells

+ Follow
Long Term Debt
$327253.00
29.04% YoYΔ $-133953.00 vs prior year quarter

Peer average

Loading

ENDRA Life Sciences- Warrants (12/05/2022) Long Term Debt History

Loading

ENDRA Life Sciences- Warrants (12/05/2022) vs. peers: Long Term Debt Comparison

Loading

ENDRA Life Sciences- Warrants (12/05/2022) Long Term Debt Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

ENDRA Life Sciences- Warrants (12/05/2022) (NDRAW) FAQ

As of the most recent data (March 2026), NDRAW shows a long-term debt of $330K. That compares with $460K in the prior-year period — down 29.0% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, NDRAW's long-term debt is now $330K (was $460K) — a 29.0% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether ENDRA Life Sciences- Warrants (12/05/2022) is outperforming or lagging.

Tracking NDRAW's long-term debt over time shows whether ENDRA Life Sciences- Warrants (12/05/2022) is scaling, shrinking, or reshaping that part of the business. The current reading is $330K That compares with $460K in the prior-year period — down 29.0% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this long-term debt page, Stockcircle has ENDRA Life Sciences- Warrants (12/05/2022)'s full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect long-term debt (currently $330K) with ownership activity and broader fundamentals.

ENDRA Life Sciences- Warrants (12/05/2022)'s long-term debt is $330K; compare it with other Technology names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.